The refinancing extends debt maturity by five years at zero interest cost, improving the balance sheet profile. However, the conversion feature introduces potential dilution at a 40% premium. Monitor for any accelerated share repurchases or additional 2026 note buybacks that could reduce the net cash position. The convertible arbitrage unwind by selling holders may create temporary buying pressure in the stock.
Price Chart
Executive Summary
PTC Therapeutics priced $500M of 0% convertible senior notes due 2031 (plus a $50M greenshoe) to refinance its 1.5% 2026 notes. The company will use ~$328.8M of proceeds to repurchase $222M principal of the 2026 notes at a premium, extending maturities by five years at zero interest cost. The conversion price of $107.48 represents a 40% premium over the $76.77 closing price, limiting near-term dilution.
Key Facts
- $500M aggregate principal of 0% convertible senior notes due 2031 priced on June 15, 2026
- Initial purchasers granted a 13-day option for an additional $50M in notes
- Net proceeds estimated at ~$486.8M (or ~$535.5M if greenshoe fully exercised)
- ~$328.8M of net proceeds used to repurchase $222M principal of 1.5% 2026 notes via privately negotiated transactions
- Conversion price of ~$107.48 per share, a 40% premium over the $76.77 closing price on June 15, 2026
- Notes mature June 15, 2031; no interest; PTC cannot redeem before June 20, 2029
- Remaining proceeds for general corporate purposes, including additional 2026 note repurchases
Financial Impact
Refinancing $222M of 1.5% 2026 notes with $500M of 0% 2031 notes; net proceeds after repurchase ~$158M for general corporate purposes. Interest savings of ~$3.3M/year on the repurchased portion.
Risk Factors
- Potential dilution if notes convert; full conversion would add ~4.65M shares at the initial conversion rate
- Remaining 2026 notes not repurchased still mature in 2026, requiring cash or refinancing
- Proceeds used for general corporate purposes may not generate sufficient returns to offset dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-074292 |
| Document: tm2618041d1_ex99-1.htm | 0001104659-26-074292 |
| Document: 0001104659-26-074292-index-headers.html | 0001104659-26-074292 |
| Document: 0001104659-26-074292-index.html | 0001104659-26-074292 |
| Document: 0001104659-26-074292.txt | 0001104659-26-074292 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Insider Cluster | $69.82 $65.26 | ▼ −6.53% | ▼ −6.00% | $63.46 (−9.11%) |
Jul 16, 2026 11w ago | Press Release | $78.52 $71.97 | ▲ +8.34% | ▲ +11.96% | $63.46 (+19.18%) |
Jul 16, 2026 11w ago | Insider Cluster | $78.52 $71.97 | ▼ −8.34% | ▼ −11.96% | $63.46 (−19.18%) |
Jul 13, 2026 11w ago | Insider Cluster | $81.33 $74.63 | ▼ −8.24% | ▼ −11.42% | $63.46 (−21.97%) |
Jul 8, 2026 12w ago | Insider Cluster | $88.57 $69.21 | ▼ −21.86% | ▼ −25.13% | $63.46 (−28.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $81.57 $76.82 | ▼ −5.82% | ▼ −5.54% | $63.46 (−22.20%) |
Jun 16, 2026 15w ago | 8-K | $73.27 $78.06 | ▲ +6.54% | ▲ +6.34% | $63.46 (−13.39%) |
Jun 9, 2026 16w ago | 8-K | $73.35 $89.55 | ▲ +22.09% | ▲ +18.46% | $63.46 (−13.48%) |
May 19, 2026 19w ago | Insider Cluster | $71.02 $78.98 | ▲ +11.21% | ▲ +10.47% | $63.46 (−10.64%) |
May 15, 2026 19w ago | Insider Cluster | $70.15 $73.27 | ▲ +4.45% | ▲ +2.87% | $63.46 (−9.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access